Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone for obesity-associated diastolic dysfunction and myocardial fibrosis
ACTRN12609000655246Phase 4Not yet recruiting
- Sponsor
- The University of Queensland
- Start
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of spironolactone in diastolic dysfunction and cardiac fibrosis (2 arms), sponsored by The University of Queensland. Primary endpoint: Myocardial fibrosis. Planned start Aug 2009; status: not yet recruiting.
02
Drugs
spironolactone
03
Conditions
diastolic dysfunctioncardiac fibrosis
Beyond the preview
Go deeper on ACTRN12609000655246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000655246.